Cytomegalovirus immunoglobulin, human


Concise Prescribing Info
Indications/Uses
Passive immunisation against CMV infection.
Dosage/Direction for Use
Adult : IV For kidney transplant recipients: 150 mg/kg w/in 72 hr of transplantation, then 100 mg/kg 2 wkly for 4 doses, then 50 mg/kg 4 wkly for 2 doses. For recipients of transplants other than kidney: 150 mg/kg w/in 72 hr of transplantation, then 2 wkly for 4 doses, then 100 mg/kg 4 wkly for 2 doses.
Dosage Details
Intravenous
Passive immunisation against cytomegaloviral infection
Adult: For kidney transplant recipients: 150 mg/kg IV infusion within 72 hr of transplantation, then 100 mg/kg once every 2 wk for 4 doses, then 50 mg/kg every 4 wk for 2 doses. For recipients of transplants other than kidney: 150 mg/kg within 72 hr of transplantation, then once every 2 wk for 4 doses, then 100 mg/kg every 4 wk for 2 doses. Start infusion at 15 mg/kg/hr, may increase gradually to 60 mg/kg/hr.
Contraindications
Hypersensitivity.
Special Precautions
Renal impairment. Monitor renal function regularly during treatment, discontinue if it deteriorates. Monitor for signs and symptoms of haemolysis. Pregnancy.
Adverse Reactions
Fever, chills, facial flushing, headache and nausea may occur, particularly at high rates of infusion.
Potentially Fatal: Anaphylaxis.
IV/Parenteral: C
Overdosage
Overdosage will result in symptoms resembling volume overload.
Drug Interactions
Live vaccines should be given at least 3 mth after the admin of the immunoglobulin.
Action
Description: Cytomegalovirus immunoglobulin contains IgG antibodies which are directed against cytomegalovirus. It is a passive source of antibodies used in the prophylaxis of cytomegaloviral disease associated with kidney, lung, liver, pancreas and heart transplants.
Storage
Store 2-8°C.
Disclaimer: This information is independently developed by MIMS based on Cytomegalovirus immunoglobulin, human from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in